Inhaled corticosteroids for asthma dosage

We identified seven randomised trials (5997 participants) of good quality with a duration of six months to three years. All of the trials compared ICS/LABA combination inhalers with LABA and ICS as individual components. Four of these trials included fluticasone and salmeterol monocomponents and the remaining three included budesonide and formoterol monocomponents. There was no statistically significant difference in our primary outcome , the number of patients experiencing exacerbations ( odds ratio ( OR ) ; 95% CI to ), or the rate of exacerbations per patient year (rate ratio ( RR ) ; 95% CI to ) between inhaled corticosteroids and long-acting beta 2 -agonists. The incidence of pneumonia, our co-primary outcome , was significantly higher among patients on inhaled corticosteroids than on long-acting beta 2 -agonists whether classified as an adverse event ( OR ; 95% CI to ) or serious adverse event (Peto OR ; 95% CI to ). Results of the secondary outcomes analysis were as follows. Mortality was higher in patients on inhaled corticosteroids compared to patients on long-acting beta 2 -agonists (Peto OR ; 95% CI to ), although the difference was not statistically significant . Patients treated with beta 2 -agonists showed greater improvements in pre-bronchodilator FEV 1 compared to those treated with inhaled corticosteroids ( mean difference ( MD ) mL; 95% CI to ), whilst greater improvements in health-related quality of life were observed in patients receiving inhaled corticosteroids compared to those receiving long-acting beta 2 -agonists (St George's Respiratory Questionnaire (SGRQ) MD -; 95% CI - to -). In both cases the differences were statistically significant but rather small in magnitude. There were no statistically significant differences between ICS and LABA in the number of hospitalisations due to exacerbations, number of mild exacerbations, peak expiratory flow, dyspnoea , symptoms scores, use of rescue medication, adverse events, all cause hospitalisations, or withdrawals from studies.

Another common fear about corticosteroids is that they will cause growth suppression in children. To date, many studies have been done that prove that corticosteroids do not stunt a child's growth. Six years of ongoing studies in children and adolescents who used inhaled corticosteroids show that the speed of growth may be slowed by about 1 cm. over one year in children. However, these children catch up and do attain their full adult height. In some studies, these children grew even taller than their siblings. Interestingly, poorly controlled asthma can actually contribute to growth suppression.

Inhaled corticosteroids for asthma dosage

inhaled corticosteroids for asthma dosage


inhaled corticosteroids for asthma dosageinhaled corticosteroids for asthma dosageinhaled corticosteroids for asthma dosageinhaled corticosteroids for asthma dosageinhaled corticosteroids for asthma dosage